Last updated on June 2019

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)


Brief description of study

The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort expansion to determine preliminary efficacy in participants with colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC) (Part B).

Clinical Study Identifier: NCT03515824

Find a site near you

Start Over